Why Intuitive Surgical (NASDAQ:ISRG) Stock Crashed 12% After Beating Earnings

Intuitive Surgical (NASDAQ:ISRG) crashed around 12% on Friday, one of its worst days in years, even though the company had just beaten expectations. Revenue and profit both came in ahead of forecasts, and its surgical robots are being used more than ever. So why did the stock fall so hard? The answer is a mix of an unresolved product recall, a cautious outlook from management, and a share price that had little room for disappointment.

What Intuitive Surgical Reported

The results themselves were strong.

Revenue rose to US$2.89 billion, up about 18% from a year earlier and ahead of the US$2.82 billion analysts expected. Adjusted profit was US$2.80 a share, well above the US$2.50 forecast. Profit margins also improved.

The core business kept growing nicely. The number of procedures done using Intuitive’s robots rose about 16%, and the company placed more of its da Vinci surgical systems than it did a year ago. On the numbers alone, this was a good quarter. The problem was everything around the numbers.

So Why Did the Stock Crash?

Three things spooked investors, and none of them had to do with this quarter’s profit.

The first is a lingering cloud over quality control. Earlier this year, in April, Intuitive Surgical began a worldwide recall of 454 da Vinci system components tied to a faulty part that could affect the system’s braking. This was not new news on Friday, but it was still hanging over the company. For a business whose entire reputation rests on safety and precision in the operating room, that ongoing scrutiny left investors highly sensitive to any sign of risk.

The second worry is future demand. Even with strong current numbers, management sounded cautious about what comes next. Rather than raising its full-year forecast, the company kept its procedure growth guidance steady at 13.5% to 15.5% and warned of a mild slowdown. Part of that is a specific concern: some US patients are losing health insurance coverage as pandemic-era support expires, which could reduce the number of operations. Investors had hoped for a raise, and the careful tone triggered selling.

The third is price. Even with the stock already down sharply from its highs earlier this year, it was still expensive, trading at around 43 times earnings, well above most other medical technology companies. When a stock is priced for perfection, a strong quarter is simply expected, and anything short of flawless can spark a sharp drop.

What It Means for Investors

The key thing to understand is that Intuitive’s business is not broken. It is highly profitable, its robots are used more each year, and it still dominates the robotic surgery market. This quarter proved the underlying business is healthy.

What has changed is investor confidence. The recall raises questions about safety and reputation. The cautious guidance raises questions about growth. And a still-high valuation means investors are quick to sell at the first hint of trouble. Put together, that explains why a genuine earnings beat was met with a double-digit drop.

Our take: today’s crash looks like a mix of real concern about the recall and nervous investors selling an expensive stock. For long-term investors who believe in the future of robotic surgery, a much lower price could eventually look attractive, especially given how dominant the company is. But in the short term, the stock may stay under pressure until Intuitive puts the recall behind it and shows that surgery volumes are holding up. The business is strong. Right now, though, investors are focused on the risks, not the results.